Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 1, 1996, Pages 325-331

  Christian, Bradley T ^a,b   Livni, Eli ^a,b   Babich, John W ^a,b   Alpert, Nathaniel M ^a,b   Dischino, Douglas D ^c   Ruediger, Edward ^c   Salazar, Daniel E ^c   Ford, Neville F ^c   Fischman, Alan J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 3 [3 [4 (5 METHOXY 4 PYRIMIDINYL) 1 PIPERAZINYL]PROPYL] 1H INDOLE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN; CARBON RADIOISOTOPES; FEMALE; HUMANS; MALE; PIPERAZINES; PYRIMIDINES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030436853     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. BECK, J. V. AND ARNOLD, K. J.: Parameter Estimation in Engineering and Science, John Wiley and Sons, New York, 1977.
2. 11C-raclopride. Psychopharmacology 112: 308-314, 1993.
3. BEVINGTON, P. R.: Data Reduction and Error Analysis for the Physical Sciences, McGraw-Hill, New York, 1969.
4. BOLES PONTO, L. L. AND PONTO, J. A.: Uses and limitations of positron emission tomography in clinical pharmacokinetics/pharmacodynamics. Clin. Pharmacokin. 22: Part II, 274-283, 1992.
5. DELFORGE, J., SYROTA, A. AND MAZOYER, B. M.: Identifiability analysis and parameter identification of an in vivo ligand-receptor model from PET data. IEEE Trans. Biomed. Eng. 37: 653-661, 1990a.
6. DELFORGE, J., JANIER, M., SYROTA, A., CROUZEL, C., VALLOIS, J. M., CAYLA, J., LANCON, J. P. AND MAZOYER, B. M.: Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. Circulation 82: 1494-1504, 1990b.
7. 11C-raclopride. Psychopharmacology (Berl.) 92: 278-284, 1987.
8. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl.) 99: S28-31, 1989.
9. 11C]raclopride. Psychopharmacology (Berl.) 107: 23-29, 1992.
10. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49: 538-544, 1992.
11. 18F-labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. J. Pharmacol. Exp. Ther. 259: 1351-1359, 1991a.
12. FISCHMAN, A. J., RUBIN, R. H. AND STRAUSS, H. W.: Imaging techniques in pharmacology. In New Trends in Pharmacokinetics, ed. by A. Rescigno and A. K. Thakur, NATO ASI Series, Plenum Press, New York, 1991b.
13. 18F-labeled fluconazole in normal human subjects studied with positron emission tomography. Antimicrob. Agents Chemother. 37: 1270-1277, 1993a.
14. 18F] fleroxacin in normal human subjects studied with positron emission tomography. Antimicrob. Agents Chemother. 37: 2144-2152, 1993b.
15. FISCHMAN, A. J., RUBIN, R. H. AND STRAUSS, H. W.: In vivo imaging in drug discovery and design. In Handbook of Experimental Pharmacology, Pharmacokinetics of Drugs, ed. by P. Welling and L. P. Balant, Springer-Verlag, New York, 1994.
16. 18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied with positron emission tomography. Antimicrob. Agents Chemother. 40: 659-664, 1996.
17. FOWLER, J. S., VOLKOW, N. D. AND WOLF, A. P.: Positron emission tomography, enzymes and drug research and development. In Nuclear Imaging in Drug Discovery, Development and Approval, ed. by H. D. Burns, R. Gibson, R. Danna, and P. Siegl, Birthauser, Boston, 1993.
18. 18F]fluoro-DOPA in human positron emission tomographic studies. J. Cereb. Blood Flow Metab. 11: 898-913, 1991.
19. 11C]Tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives. J. Cereb. Blood Flow Metab. 14: 85-99, 1994.
20. LIVNI, E., BABICH, J. W. AND FISCHMAN, A. J.: Robotic synthesis of F-18 and C-11 radiopharmaceuticals at Massachusetts General Hospital. J. Labelled Compd. Radiopharm. 35: 552, 1994.
21. LOEVINGER, R., BUDINGER, T. F. AND WATSON, E. E.: MIRD Primer for Absorbed Dose Calculations, rev. ed. Society of Nucelar Medicine, New York, 1991.
22. LOGAN, J., WOLF, A. P., SHIUE, C. Y. AND FOWLER, J. S.: Kinetic Modeling of receptor-ligand binding applied to positron emission tomography studies with neuroleptic tracers. J. Neurochem. 48: 73-83, 1987.
23. MINTUN, M. A., RAICHLE, M. E., KILBOURN, M. A., WOOTEN, G. F. AND WELCH, M. J.: A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 15: 217-227, 1984.
24. ROTA KOPS, E., HERZOG, H., SCHMID, A., HOLTE, S. AND FEINENDEGEN, L. E.: Performance characteristics of an eight-ring whole body PET scanner. J. Comput. Assisted Tomogr. 14: 437-445, 1990.
25. SADZOT, B. AND FRANCK, G.: Non-invasive methods to study drug disposition: Positron emission tomography detection and quantification of brain receptors in man. Drug Metab. Pharmacokin. 15: 135-142, 1990.
26. SALAZAR, D. E., UDERMAN, H. D., BEHR, D. A., SHYU, W-C., MANNING, J. A., LUCKI, I., SCHUSTER, A., SMITH, R. A. AND FORD, N. F.: The clinical pharmacology of BMS-181101 assessed in healthy male subjects. Presented at American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1995.
27. SWART, J. A. A., VAN DER WARF, J. F., WIEGMAN, T., PAANS, A. M. J., VAALBURG, W. AND KORF, J.: In vivo binding of spiperoine and N-methylspiperone to dopaminergic and serotonergic sites in the rat brain: Multiple modeling and implications for PET scanning. J. Cereb. Blood Flow Metab. 10: 297-306, 1990.